Azintuxizumab, CAS 1826819-57-1

Product Description: Azintuxizumab (ABBV-383; PR-1471272) is an IgG4 T cell-engaging bispecific mAb (T-BsAb) targeting B cell maturation antigen (BCMA). Azintuxizumab has the potential to be used in relapsed/refractory multiple myeloma (RRMM) research. Azintuxizumab is composed of two heavy chains and one light chain: the heavy chain (human CD319 antigen and human-mouse monoclonal PR-1471272, respectively) and the light chain (human-mouse monoclonal PR-1471272) are connected by disulfide bonds and can bind to CD3 (Kd=1.3 μM). Azintuxizumab can form ADC conjugates with derivatives of hemistarlin (HY-117371)[1].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]D'Souza A, et al. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2022 Nov 1;40(31):3576-3586./[2]Hemiastarlin derivative and antibody-drug conjugates including same. World Intellectual Property Organization, WO2019031615 A1 2019-02-14 .

CAS Number: 1826819-57-1

Molecular Weight: N/A

Compound Purity: 99.0

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: ADC Antibody;CD3

• Artikelnummer: MEXHY-P99453-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99453-10
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated